Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC-101 in Dual-Cord Blood Transplantation for Hematologic Malignancies
NCT01983761Phase 2Unknown
- Sponsor
- Targazyme
- Start
- Nov 2013
- Primary completion
- Mar 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of TZ101 in hematologic malignancy, myelodysplastic syndrome (MDS), sponsored by Targazyme. Status: unknown.
02
Drugs
TZ101
03
Conditions
hematologic malignancymyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01983761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983761.